More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$9.94B
P/E ratio
20
Dividend yield
0.3492%
Expense ratio
0.35%
Beta
0.86596
Previous close
$145.88
Today's open
$147.07
Day's range
$143.24 - $147.72
52 week range
$113.06 - $169.89
Industries
Health
MRNA
Moderna Inc
2.43%
EXEL
Exelixis Inc
1.79%
1.79%
AMGN
Amgen Inc
1.77%
1.77%
BIIB
Biogen Inc
1.76%
1.75%
1.74%
NTRA
Natera Inc
1.71%
ABBV
AbbVie Inc
1.71%
Decoding Healthcare ETFs: Different Sectors, Different Strategies
While State Street SPDR S&P Biotech ETF delivered a higher 1-year total return, the Invesco fund has experienced significantly shallower drawdowns and stronger cumulative growth over the past five years. The Invesco fund offers a slightly higher dividend yield, though the State Street fund remains the larger and more cost-efficient option for investors seeking targeted industry exposure.
The Motley Fool • Nov 7, 2026

IYH and XBI: Two Distinct Paths to Investing in Healthcare
iShares U.S. Healthcare ETF tracks a broad mix of pharmaceutical and medical device companies, while State Street SPDR S&P Biotech ETF focuses strictly on the biotechnology sub-industry. State Street SPDR S&P Biotech ETF has delivered a higher 1-year total return but experienced a significantly deeper maximum drawdown of 53.2%.
The Motley Fool • Nov 7, 2026

Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
U.S. midterm results signal a "Blue Wave," with Democrats controlling both House and Senate, likely impacting healthcare policy and funding. Health insurers like UnitedHealth and CVS Health typically rebound after policy shocks; Oscar Health stands out for ACA-driven growth and innovation.
Seeking Alpha • Nov 5, 2026

Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
Tempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.
24/7 Wall Street • Nov 2, 2026

Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.
24/7 Wall Street • Oct 30, 2026

ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
Zacks Investment Research • Oct 28, 2026

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.
Zacks Investment Research • Oct 26, 2026

Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million
Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.
24/7 Wall Street • Oct 20, 2026

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
Market Watch • Oct 15, 2026

From Laggard to Leader: The Surprising Comeback of Healthcare
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
ETF Trends • Oct 13, 2026

¹ Disclosures

Open an M1 investment account to buy and sell SPDR S&P Biotech ETF commission-free¹. Build wealth for the long term using automated trading and transfers.